wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q36649978-B82EF7F2-9E41-4E7D-8EC5-13EA7D101444
Q36649978-B82EF7F2-9E41-4E7D-8EC5-13EA7D101444
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36649978-B82EF7F2-9E41-4E7D-8EC5-13EA7D101444
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.
P2860
Q36649978-B82EF7F2-9E41-4E7D-8EC5-13EA7D101444
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36649978-B82EF7F2-9E41-4E7D-8EC5-13EA7D101444
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
59992d0a4f1ac62d11948c48ea53bbbb53b0fbfc
P2860
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.